Biodistribution and radiation dose estimates for 68 Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

Purpose Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In this study, we assess the feasibility of using the novel somatostatin antagonist 68Ga-DOTA-JR11 for PET imaging of NETs.